As Th17 cells are likely involved in the progression of disease severity, but not in the initial onset of T1D, targeting the inflammatory properties of Th17 cells may have efficacy in early onset T1D patients; as this may delay the total ablation of insulin-producing pancreatic β-cells and therefore the dependence on exogenously-derived insulin for survival. This evidence concerns the gene INS and type 1 diabetes mellitus.